Home > Insider Trading > Filing (0000899243-22-031043)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
891293	Cti Biopharma Corp	CTIC	Pharmaceutical Preparations (2834)	911533912

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1339498	R Adam Craig	3101 Western Avenue, Suite 800 Seattle WA 98121	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-09-12	242,300	$0.84	270,161	No	4	M	Direct
Common Stock	Disposition	2022-09-12	242,300	$6.43	27,861	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2022-09-12	242,300	$0.00	242,300	$0.84

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
913,254		2029-05-16	No	4	M	Direct

Footnotes

This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person.
The reporting person's sale of common stock reported herein may be deemed to be matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 5,000 shares of common stock purchased by the reporting person on August 16, 2022. The reporting person has sent to the Issuer the full amount of the disgorgeable profit arising from the sale reported herein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.27 to $6.58, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
One third of the shares underlying the option vested on 2/19/2020 and annually thereafter until all the underlying shares were fully vested on 2/19/2022.